Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cefiderocol sulfate tosylate by Shionogi for Resistant Pseudomonas aeruginosa Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Resistant Pseudomonas aeruginosa Infections. According...
Cefiderocol sulfate tosylate by Shionogi for Klebsiella pneumoniae Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Klebsiella pneumoniae Infections. According to...
Cefiderocol sulfate tosylate by Shionogi for Enterobacteriaceae Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Enterobacteriaceae Infections. According to GlobalData,...
Cefiderocol sulfate tosylate by Shionogi for Acinetobacter Infections: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Acinetobacter Infections. According to GlobalData,...
Cefiderocol sulfate tosylate by Shionogi for Sepsis: Likelihood of Approval
Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Sepsis. According to GlobalData, Phase...